Keros Therapeutics, Inc. (KROS) स्टॉक विश्लेषण

कंपनी का अवलोकन

Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development and commercialization of novel therapeutics designed to address patient disorders associated with dysfunctional signaling within the transforming growth factor-beta family of proteins in the United States. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to leverage specialized scientific research and regulatory pathways typical of this segment. At the current reporting period, the entity holds a market capitalization of $380.52M, generates annual revenue of $244.06M, and employs a workforce of 78 individuals. These valuation and revenue figures indicate that while the company possesses a significant market presence relative to its employee count, its financial scale reflects the capital-intensive nature of biotechnology development where substantial cash reserves are often required to fund ongoing research and commercialization efforts.

वित्तीय स्वास्थ्य

Keros Therapeutics reported revenue of $244.06M over the trailing twelve months, with a corresponding net income of $87.01M and an EBITDA of $72.08M. The substantial gap between the revenue figure of $244.06M and the net income of $87.01M reveals a cost structure where operating expenses, while high, have been managed to maintain profitability, though the operating margin presents a complex picture. The company maintains free cash flow of $66.24M, which signifies strong financial flexibility allowing for potential reinvestment in R&D or strategic acquisitions without immediate reliance on external capital markets. Analysis of the three primary margins shows a gross margin of 47.9%, indicating healthy pricing power or low cost of goods sold relative to sales; however, the operating margin stands at -7576.6%, which is an anomalous figure suggesting significant non-operating charges or specific accounting adjustments in the reporting period, while the profit margin remains at 35.7%, confirming that the company remains profitable on a net basis despite the operating metric distortion. On the balance sheet, the company holds $287.42M in cash against $16.88M in debt, supported by a debt-to-equity ratio of 5.57, indicating a leveraged position where equity is relatively low compared to debt obligations. The current ratio is reported at 15.45, which indicates an exceptionally strong short-term liquidity position, suggesting the company has ample current assets to cover its current liabilities many times over. Return on Equity stands at 19.9% and Return on Assets is 9.2%, metrics that reveal management is generating significant returns on shareholder capital and utilizing assets efficiently to produce earnings.

मूल्यांकन आकलन

The valuation metrics for Keros Therapeutics show a trailing P/E ratio of 5.45 and a forward P/E of -2.47. The divergence between the positive trailing P/E and the negative forward P/E implies that while the company has generated earnings recently, future earnings expectations are currently negative or undefined, likely due to the forward-looking nature of the metric incorporating anticipated losses or specific accounting treatments. The price-to-book ratio is 0.81, indicating that the market values the company at less than its book value, suggesting no market premium over the tangible net assets of the firm. Alternative valuation metrics include a price-to-sales ratio of 1.56 and an EV/EBITDA of -0.34; these figures suggest that investors are pricing the stock based on revenue multiples rather than earnings multiples due to the negative forward earnings outlook. Regarding price levels, the 52-week high is $22.55 and the 52-week low is $9.12, and the current trading price sits within this range, reflecting the volatility typical of biotechnology stocks. The beta value is 0.99, which means the stock's price volatility relative to the broader market is roughly equivalent to the market average, moving in tandem with general market fluctuations without significant amplification or dampening.

Growth & Income

The revenue growth year-over-year is -87.3%, while earnings growth is listed as N/A. The negative revenue growth rate combined with the N/A earnings growth status implies a significant contraction in sales volume or a fundamental shift in the commercialization phase of the product pipeline. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all earnings back into operations and growth initiatives rather than distributing cash to shareholders. The overall growth and income profile for Keros Therapeutics is characterized by a contraction in revenue, a lack of dividend income, and a reliance on internal cash generation and existing cash reserves to sustain operations and fund future development milestones.